U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07464210) titled 'Nemtabrutinib, Bortezomib, and Rituximab for WM' on March 02.
Brief Summary: This is a phase II (2 parts), open-label, single arm, multicenter study to evaluate the efficacy and safety of nemtabrutinib in combination with bortezomib and rituximab
Study Start Date: June 01, 2026
Study Type: INTERVENTIONAL
Condition:
Waldenstrom Macroglobulinemia
Intervention:
DRUG: NEBULA
Nemtabrutinib + Bortezomib + Rituximab
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Seoul National University Hospital
Information provided by (Responsible Party): JaMin Byun, Seoul National University Hospital
Published by HT Digital Content Services...